Moderna announces positive results for Omicron vaccine / Photo: Joseph Prezioso - AFP
NYSE - LSE
| RIO | -1.45% | 58.55 | $ | |
| RBGPF | 100% | 67.21 | $ | |
| CMSC | 0.09% | 22.03 | $ | |
| RYCEF | -0.99% | 10.12 | $ | |
| BTI | -0.58% | 43.3 | $ | |
| RELX | -1.02% | 54.08 | $ | |
| VOD | -0.31% | 9.73 | $ | |
| GSK | -2.84% | 38.75 | $ | |
| AZN | -1.82% | 70.51 | $ | |
| NGG | -1.88% | 71.65 | $ | |
| SCS | -0.51% | 9.87 | $ | |
| BCC | -0.61% | 92.71 | $ | |
| CMSD | -0.18% | 22.26 | $ | |
| BP | 1.51% | 27.88 | $ | |
| JRI | 0.77% | 13.01 | $ | |
| BCE | -3.78% | 21.44 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
S.Leroy--MJ
